


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-19.19%
-25.72%
+9.03%
-5.38%
-4.47%
JNJ
Johnson & Johnson
$237.79
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Trading below its fair value
JNJ Price Performance
$204.39 (+16.34%)
$193.83 (+22.68%)
$177.4 (+34.04%)
$163.74 (+45.22%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
JNJ Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
JNJ has Low risk level

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Feb 02, 2026
Upgrade
Overweight
Morgan Stanley
Jan 28, 2026
Upgrade
Overweight
Morgan Stanley
Dec 17, 2025
Price Target Raised
Neutral
BofA
Dec 12, 2025
Reiterate
Buy
Citigroup
Dec 12, 2025
Reiterate
Outperform
RBC
NBTX
Nanobiotix S.A. American
21.03
-3.22%
BLTE
Belite Bio Inc
178.33
-2.44%
ANNX
Annexon
5.63
-6.79%
SNDX
Syndax Pharmaceutica
20.15
-1.37%
REGN
Regeneron Pharma
766.63
-1.09%
What is JNJ current stock price?
What are JNJ stock strengths?
What is JNJ Risk Level?
What is JNJ market cap and volume?
What is JNJ current Stock IQ?
Should I buy JNJ stock right now?
Is JNJ a Strong Buy right now?
What does a 'Strong Buy' rating mean for JNJ?
What does a 'Strong Sell' rating mean for JNJ?
What factors influence JNJ's Stock IQ?
Join over 5,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-19.19%
-25.72%
+9.03%
-5.38%
-4.47%
JNJ
Johnson & Johnson
Current Price
$237.79
Runners Also Watch
NBTX
Nanobiotix S.A. American
21.03
-3.22%
BLTE
Belite Bio Inc
178.33
-2.44%
ANNX
Annexon
5.63
-6.79%
SNDX
Syndax Pharmaceutica
20.15
-1.37%
REGN
Regeneron Pharma
766.63
-1.09%

JNJ Price Performance
$204.39 (+16.34%)
$193.83 (+22.68%)
$177.4 (+34.04%)
$163.74 (+45.22%)
JNJ Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Reported a strong earnings

Earnings increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive

Pays a reliable dividend

Expands stock buyback program
Future
Future

Earnings are forecast to grow

Outperform the market

Trading below its fair value
![]()
JNJ Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
JNJ Street Sentiment is extremely bullish and have positive views on the near-term outlook
JNJ has Low risk level

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Feb 02, 2026
Upgrade
Overweight
Morgan Stanley
Jan 28, 2026
Upgrade
Overweight
Morgan Stanley
Dec 17, 2025
Price Target Raised
Neutral
BofA
Dec 12, 2025
Reiterate
Buy
Citigroup
Dec 12, 2025
Reiterate
Outperform
RBC
JNJ Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow

Upgraded on attractively valued

Outperform the market

Trading below its fair value
JNJ Latest Analysis
RBC Sees Johnson & Johnson (JNJ) Well Positioned to Manage Legal Overhang. Johnson &. Johnson (NYSE:JNJ) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. On February 3 RBC Capital raised its price target on Johnson &. Johnson (NYSE:JNJ) to $255 from $240 and reiterated an Outperform rating. The firm said the company is unlikely to reverse the core implications of the Daubert [….]
Today
J&J Snack Foods (JJSF) Loses 11% in 4 Weeks Heres Why a Trend Reversal May be Around the Corner. The heavy selling pressure might have exhausted for J&J Snack Foods (JJSF) as it is technically in oversold territory now. In addition to this technical measure strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wed Feb 4, 2026
Johnson & Johnsons Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy?. Key PointsJohnson & Johnsons growth rate improved this past year and that trend is likely to continue.
Wed Feb 4, 2026
Relative Strength Alert For J&J Snack Foods . The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two important characteristics &mdash. strong fundamentals and a valuation that looks inexpensive.
Tue Feb 3, 2026
J&J Snack Foods falls after the bakery business disappointed in FQ1.
Tue Feb 3, 2026
Morgan Stanley Upgrades Johnson & Johnson to Overweight Increases PT to $262. Johnson &. Johnson (NYSE:JNJ) is one of the 10 Hottest Stocks to Buy in 2026. On January 28 TheFly reported that Morgan Stanley upgraded Johnson &. Johnson (NYSE:JNJ) from Equal Weight to Overweight increasing the price target from $200 to $262. Terence Flynn from Morgan Stanley remains ish on the company as he expects higher [….]
Mon Feb 2, 2026
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over.
Fri Jan 30, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.